Rockefeller Capital Management
FPRX

Rockefeller Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Rockefeller Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-6,444
Closed -$111K – 794
2018
Q1 		$111K Buy
+6,444
New +$126K ﹤0.01% 366

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Rockefeller Capital Management's FPRX Position: Q2 2018 in Review

Rockefeller Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2018, closing a stake of 6,444 shares — an estimated $111K sold.

Rockefeller Capital Management first reported a position in FPRX in Q1 2018 and held it in 1 quarter. The position peaked at $111K in Q1 2018. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2018.

  • Rockefeller Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Rockefeller Capital Management sold 6,444 Five Prime Therapeutics, Inc. shares in Q2 2018, an estimated $111K.
  • Rockefeller Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2018 and held it in 1 quarter.
  • Rockefeller Capital Management's Five Prime Therapeutics, Inc. position peaked at $111K in Q1 2018.
  • 123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2018.

Based on Rockefeller Capital Management's 13F filing for Q2 2018, filed 31 Jul 2018.